Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And By Segment Forecasts, 2023-2031

Gastroretentive Drug Delivery Systems Outsourcing Market Size is valued at USD 1.26 Bn in 2022 and is predicted to reach USD 2.32 Bn by the year 2031 at a 7.22% CAGR during the forecast period for 2023-2031.

Gastroretentive drug delivery systems are designed for extended retention within the stomach, allowing for direct interaction with ulcer sites and thereby increasing drug concentrations specifically at the affected areas. These systems enable sustained drug release and localized dosage delivery in the stomach and small intestine. The rising incidence of disorders related to the stomach and small intestine is anticipated to drive market demand.

Furthermore, the global increase in disease burdens, coupled with the demonstrated effectiveness of gastroretentive drug delivery systems in addressing conditions like peptic ulcers and gastric ulcers, is a significant driver for the market's expansion in the foreseeable future. These systems extend the retention time in the stomach, leading to enhanced drug concentration at the target site of application. Consequently, this improves drug bioavailability and reduces the required dosage, fueling the growth of the global gastroretentive drug delivery systems market.

Additionally, the growing prevalence of H. Pylori infection, responsible for gastritis, gastric cancer, and gastroduodenal ulcer disease, is also likely to contribute to market growth. Challenges related to ensuring that outsourcing partners possess adequate production capacity and scalability to meet escalating demand can be particularly limiting, especially during periods of rapid market growth.

Competitive Landscape

Some Major Key Players In The Gastroretentive Drug Delivery Systems Outsourcing Market:

• Catalent
• Lonza
• Evonik
• Colorcon
• Quotient Sciences
• Aptar Pharma
• Aenova Group
• Evotec
• Vectura Group Ltd.
• Ashland
• Calera Corporation
• Others

Market Segmentation:

The gastroretentive drug delivery systems outsourcing market is segmented on the basis of the dosage form. According to dosage form, the market is segmented as tablets, liquid, microspheres, capsules and others.

The Tablets Segment Witnessed Growth At A Rapid Rate.

The tablets segment is projected to grow rapidly in the global gastroretentive drug delivery systems outsourcing market. The growing emphasis of manufacturers on developing gastroretentive tablets is anticipated to propel the segment's expansion. Gastroretentive tablets are designed to offer controlled and prolonged release of medication, ensuring a consistent and sustained level of drugs in the bloodstream over an extended duration. This controlled release mechanism reduces the need for frequent dosing, enhancing patient convenience. Additionally, gastroretentive tablets can potentially enhance the bioavailability of certain medications, especially those with limited solubility or permeability.

In The Region, The North American Gastroretentive Drug Delivery Systems Outsourcing Market Holds A Significant Revenue Share.

The North American gastroretentive drug delivery systems outsourcing market is expected to record the maximum market share in terms of revenue in the near future. The expansion of this particular regional market can be attributed to the significant patient population it serves. Furthermore, the market is set to grow with the boost provided by increasing government backing for the pharmaceutical sector. In addition, Asia Pacific is estimeted to grow at a rapid rate in the global gastroretentive drug delivery systems outsourcing market. Several Asian nations have established regulations and incentives aimed at fostering pharmaceutical research and development, particularly in the realm of drug delivery technology. These initiatives hold the promise of attracting both domestic and international companies in search of outsourcing collaborations. 

Recent Developments:

• In August 2022, Catalent revealed its intention to purchase Metrics Contract Services for USD 475 million. This strategic move aims to enhance Catalent's promising capabilities and increase its oral development and manufacturing capacity.

Gastroretentive Drug Delivery Systems Outsourcing Market Report Scope